Dear Editor, We describe the diagnostic characteristics of three pediatric patients with early T-cell precursor (ETP)-ALL. All three patients had hyperleukocytosis with a white blood cell (WBC) count of more than 100.0 × 10 9 /L, showed immunophenotypic findings consistent with ETP-ALL, and were positive for FLT3 mutations. The clinical and laboratory findings, including immunophenotyping results (Fig. 1) , T-cell receptor (TCR) rearrangements, Fms-related tyrosine kinase 3 (FLT3) mutations, and karyotype results, for the three patients are summarized in Table 1 . The aim of this report is to provide information on ETP-ALL and reveal the immunophenotypic and molecular characteristics of ETP-ALL in pediatric patients.
Dear Editor, We describe the diagnostic characteristics of three pediatric patients with early T-cell precursor (ETP)-ALL. All three patients had hyperleukocytosis with a white blood cell (WBC) count of more than 100.0 × 10 9 /L, showed immunophenotypic findings consistent with ETP-ALL, and were positive for FLT3 mutations. The clinical and laboratory findings, including immunophenotyping results (Fig. 1 ), T-cell receptor (TCR) rearrangements, Fms-related tyrosine kinase 3 (FLT3) mutations, and karyotype results, for the three patients are summarized in Table 1 . The aim of this report is to provide information on ETP-ALL and reveal the immunophenotypic and molecular characteristics of ETP-ALL in pediatric patients.
A 14-yr-old boy presented with dizziness, vomiting, and otalgia lasting for several weeks. Laboratory tests showed WBC count of 402. ETP-ALL is a T-ALL subtype with a very high risk of remission induction failure, relapse, and overall poor prognosis; it is characterized by a specific immunophenotype, i.e., CD1a(-), CD8(-), CD5 weak, with one or more stem cell or myeloid-associated markers [1, 2] . Our three patients showed very similar immunophenotypic patterns, with common expression of cCD3, T-cell markers (e.g., CD2 and CD7), and stem cell or myeloid/stem cell markers (e.g., CD34 and CD117) ( Table 1 ). The myeloid marker CD13 was expressed in two patients and the myeloid/ monocytic marker CD64 was expressed in one patient. Although weak or negative CD5 was initially a part of the diagnostic criteria for ETP-ALL [1] , the optimal aggregate of immunophenotypic markers for ETP leukemic cell identification is unknown. In a re-cent study, for example, CD4 and CD8 double negativity, in addition to CD34 or CD13/CD33 expression predicted 10 out of 13 cases with an ETP-ALL gene signature [3] .
T-ALL shows a very high incidence of clonal rearrangements of TCR genes [4] . In our case series of ETP-ALL patients, TCR rearrangement was found in one (TCRγ) of the three patients, in contrast to a previous study that found TCR rearrangements in eight of nine ETP-ALL patients [1] . The development of the pro-T-cell, including the ETP stage, may be independent of TCR rearrangement because it is involved in the initial phase of T-cell differentiation, which is coordinated by the migration of distinct thymic microenvironments [5] . CD4 and CD8 double negative [6] . TCR rearrangement starts at DN2 with the TCRδ locus, followed by TCRγ and TCRβ, and rearrangement is completed during DN3 [7] . FLT3 mutations, such as internal tandem duplications (ITDs), are the most common somatic alterations in AML and predict a poor prognosis [8] . FLT3 mutations were detected in all three patients, consistent with a previous study that reported a high frequency (35%) of FLT3 mutations in ETP-ALL and found that FLT3 mutations are less strongly associated with TCR rearrangements than wild-type FLT3 in ETP-ALL [9] . The coexistence of FLT3 mutations and CD117/KIT expression in our patients was consistent with previous results that T-ALL patients with CD117/ KIT expression tend to harbor FLT3 mutations [10] .
Although the three patients responded well to remission induction chemotherapy and have maintained CR (Table 1) , we emphasize the need for close follow-up because ETP-ALL has a high risk of relapse, especially in children [2] . ETP-ALL has recently been recognized as a distinct entity within ALL; accordingly, literature on the diagnosis and treatment of ETP-ALL is limited. The morphological, immunophenotypic, and molecular characterization of three pediatric ETP-ALL patients in this study may aid in the diagnosis of this rare, but important subtype of acute leukemia.
